I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

EURETINA 2022

-
Coming soon
10:30 AM
09:02 AM
Duration 6mins Congress Center Hamburg, Germany
Patient Experience with Anti-VEGF Intravitreal Injections in Neovascular Age-related Macular Degeneration and Diabetic Macular Edema: A Multinational Observational Study
Giocanti A, Holekamp N, Sheeth V, Peto T, Kertes P, Layana AG, Viola F, Barbier V, Lewis H, Lambert J, Gentile B, Chi G, Mirt M
11:14 AM
11:32 AM
Duration 6mins Congress Center Hamburg, Germany
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials
Figueroa M, Pearce I, Demetriades AM, Kotecha A, Silverman D, Swaminathan B, Patel V, Lin H
Duration 6mins Congress Center Hamburg, Germany
Faricimab in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Interval Cohort in the Phase 3 TENAYA and LUCERNE Trials
Lai T, Michels S, Demetriades AM, Quezada Ruiz C, Silverman D, Ives J, Swaminathan B, Lin H
12:23 PM
Duration 6mins Congress Center Hamburg, Germany
Personalised Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
Korobelnik JF, Jaffe GJ, Gerendas BS, Abreu F, Camino A, Jain N, Tang Y, Haskova Z
12:29 PM
Duration 6mins Congress Center Hamburg, Germany
Angiopoietin-2 signalling and vascular stability with faricimab in diabetic macular edema
Joussen A, Willis JR, Haskova Z, Westenskow PD, Lin H
12:35 PM
Duration 6mins Congress Center Hamburg, Germany
Predicting 5-year progression to vision-threatening complications using machine learning
Cunha-Vaz J, Dampolous D, Mendes L, Santos T, Neubert A, Ferrara D, Benmansour F
12:53 PM
Duration 6mins Congress Center Hamburg, Germany
VOYAGER: An Innovative, Global, Observational Study to Gain Real-world Insights Into the Long-term Utilisation of the Port Delivery System With Ranibizumab and Faricimab for the Treatment of nAMD and DME
Guymer R, Bailey C, Chaikitmongkol V, Chakravarthy U, Chaudhary V, Finger R, Gallego R, Koh A, Lövestam M, Parravano M, Luna Pinto JD, Schmitz-Valckenberg MS, Sheth V, Souied E, Chi G, Glittenberg C, Scheidl S, Bengus M
01:05 PM
Duration 6mins Congress Center Hamburg, Germany
Deep Learning Model to Identify Moderately Severe and Severe Non-proliferative Diabetic Retinopathy From 7-Field Colour Fundus Photographs
Cunha-Vaz J, Dampoloulos D, Yang Q, Neubert A, Mendes L, Santos T, Sredar N, Ferrara D, Benmansour F
01:23 PM
03:29 PM
Duration 6mins Congress Center Hamburg, Germany
Key Clinical Pearls for Evaluating Surgical Candidates, and Patient Preference, for the Port Delivery System With Ranibizumab
Figueroa M, Holekamp N, Bobbala A, Callaway N, DeGraaf S, Menezes A, Heinrich D
03:35 PM
03:41 PM
Duration 6mins Congress Center Hamburg, Germany
Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab
Khanani A, Singh N, Barteselli G, Callaway N, Patel S, Jaycock P, Menezes A, Malhotra V
04:27 PM
Duration 6mins Congress Center Hamburg, Germany
Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Schlottmann PG, Wells JA, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H
04:32 PM
Duration 6mins Congress Center Hamburg, Germany
HONU: A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Guymer R, Wu Z, Datta S, Steffen V, Gao S, Zhang M, Litts KM, Chang MC, Elstrott J, Zhang J, Liu L, Willis J, Chen H
05:08 PM
Duration 6mins Congress Center Hamburg, Germany
Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration: End-of-Study Results
Rizzo S, Brooks L, Mittra R, Wykoff C, Callaway N, DeGraaf S, Fung AE, Gune S, LePogam S, Smith R, Willis J, Barteselli G
05:14 PM
03:12 PM
Duration 5mins Congress Center Hamburg, Germany
Quantification of Lesion Progression of Incomplete and Complete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration
Schmitz-Valckenberg S, Sassmannshausen M, Braun M, Steffen V, Gao S, Honigberg L, Ferrara D, Pfau M, Holz